Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.

中文翻译：

---

武装雄激素受体以对抗乳腺癌中的致癌雌激素受体活性

大多数乳腺癌是由雌激素受体α (ER) 的致癌活性驱动的。对 ER 靶向治疗的耐药性是乳腺癌死亡的主要原因。最近，人们对靶向雄激素受体 (AR) 治疗 ER 驱动的乳腺癌重新产生了兴趣。在此，我们讨论了 AR 激动剂而非拮抗剂治疗策略的证据。